Cellosaurus cell line CD#68T-13 iPSC (CVCL

Cross-references
Cell line name	CD#68T-13 iPSC
Synonyms	CD68T-13 iPSC
Accession	CVCL_A5RU
Resource Identification Initiative	To cite this cell line use: CD#68T-13 iPSC (RRID:CVCL_A5RU)
Comments	Population: Jewish. Characteristics: Using TALEN a EF1a promoter-ASPA-T2A-CD19t construct was introduced in the AAVS1 safe harbor locus (PubMed=33304759). Genetic integration: Method=TALEN; Gene=HGNC; HGNC:756; ASPA. Genetic integration: Method=TALEN; Gene=HGNC; HGNC:1633; CD19 (Note=With p.Lys324_Arg556del = CD19t). Cell type: Fibroblast; CL=CL_0000057.
Sequence variations	Mutation; HGNC; HGNC:756; ASPA; Simple; p.Glu285Ala (c.854A>C); ClinVar=VCV000002605; Zygosity=Homozygous (PubMed=33304759).
Disease	Canavan disease (NCIt: C84611) Canavan disease (ORDO: Orphanet_141)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_A5RM (CD#68 iPSC)
Sex of cell	Male
Age at sampling	2Y
Category	Induced pluripotent stem cell
Publications	PubMed=33304759; DOI=10.1002/advs.202002155; PMCID=PMC7709977 Feng L.-Z., Chao J.-F., Tian E., Li L., Ye P., Zhang M., Chen X.-W., Cui Q., Sun G.-H., Zhou T., Felix G., Qin Y., Li W.-D., Meza E.D., Klein J., Ghoda L.Y., Hu W.-D., Luo Y.-L., Dang W., Hsu D., Gold J.D., Goldman S.A., Matalon R.K., Shi Y.-H. Cell-based therapy for Canavan disease using human iPSC-derived NPCs and OPCs. Adv. Sci. (Weinh.) 7:2002155.1-2002155.19(2020)
Encyclopedic resources	Wikidata; Q107114635
Entry history
Entry creation	20-May-2021
Last entry update	19-Dec-2024
Version number	7